Shares of Globus Medical, Inc. (NYSE:GMED – Get Free Report) have been given a consensus recommendation of “Hold” by the twelve research firms that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, seven have assigned a hold recommendation and four have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $65.11.
GMED has been the topic of a number of recent analyst reports. Stifel Nicolaus upgraded shares of Globus Medical from a “hold” rating to a “buy” rating and set a $61.00 price target on the stock in a research report on Monday, September 18th. Wells Fargo & Company dropped their price target on shares of Globus Medical from $63.00 to $58.00 and set an “equal weight” rating on the stock in a research report on Friday, September 15th. StockNews.com assumed coverage on shares of Globus Medical in a research report on Thursday, October 5th. They set a “hold” rating on the stock. TheStreet downgraded shares of Globus Medical from a “b-” rating to a “c+” rating in a research report on Thursday, August 31st. Finally, Barclays boosted their target price on shares of Globus Medical from $77.00 to $86.00 and gave the company an “overweight” rating in a research report on Thursday, October 12th.
Institutional Inflows and Outflows
Globus Medical Trading Down 0.4 %
GMED opened at $45.38 on Tuesday. Globus Medical has a fifty-two week low of $43.38 and a fifty-two week high of $80.04. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.47 and a quick ratio of 2.36. The firm has a market capitalization of $4.56 billion, a price-to-earnings ratio of 29.28, a PEG ratio of 1.73 and a beta of 1.10. The company’s 50 day moving average price is $49.28 and its two-hundred day moving average price is $54.30.
Globus Medical (NYSE:GMED – Get Free Report) last posted its earnings results on Tuesday, November 7th. The medical device company reported $0.57 earnings per share for the quarter, topping analysts’ consensus estimates of $0.54 by $0.03. The firm had revenue of $383.60 million for the quarter, compared to analyst estimates of $306.78 million. Globus Medical had a net margin of 12.88% and a return on equity of 9.79%. The company’s revenue for the quarter was up 51.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.50 EPS. As a group, research analysts predict that Globus Medical will post 2.31 earnings per share for the current year.
About Globus Medical
Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. It offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional pain management solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.
- Five stocks we like better than Globus Medical
- 3 Monster Growth Stocks to Buy Now
- Safeguard your portfolio with these three bargain stocks
- What Does the Consumer Price Index Measure?
- Membership clubs gain leverage for the consumer rebound
- How to Invest in Blockchain Stocks Step by Step
- Advanced Auto Parts may be worth more in pieces than the whole
Receive News & Ratings for Globus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical and related companies with MarketBeat.com's FREE daily email newsletter.